Fintel reports that on April 8, 2026, Needham initiated coverage of MapLight Therapeutics (NasdaqGS:MPLT) with a Buy recommendation.
Analyst Price Forecast Suggests 34.09% Upside
As of March 27, 2026, the average one-year price target for MapLight Therapeutics is $32.44/share. The forecasts range from a low of $28.28 to a high of $36.75. The average price target represents an increase of 34.09% from its latest reported closing price of $24.19 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for MapLight Therapeutics is 0MM. The projected annual non-GAAP EPS is -3.74.
What is the Fund Sentiment?
There are 78 funds or institutions reporting positions in MapLight Therapeutics. This is an increase of 76 owner(s) or 3,800.00% in the last quarter.
What are Other Shareholders Doing?
Novo Holdings A holds 3,687K shares representing 9.01% ownership of the company.
Fcpm Iii Services B.v. holds 3,226K shares representing 7.89% ownership of the company.
T. Rowe Price Investment Management holds 2,799K shares representing 6.84% ownership of the company.
Goldman Sachs Group holds 1,937K shares representing 4.73% ownership of the company.
Nan Fung Group Holdings holds 971K shares representing 2.37% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
